H. Park (Seoul, Republic of Korea), D. Toumpanakis (Athens, Greece)
Trends in primary outcome parameters for respiratory trials.
R. Lins (Antwerpen, Belgium), M. Lins (Mechelen, Belgium), H. Pillu (Antwerpen, Belgium), B. Volckaert (Antwerpen, Belgium), A. Ghalamkarpour (Mechelen, Belgium), K. Timmermans (Mechelen, Belgium)
|   |
Effect of association with Indacaterol/Glycopirronium on Atrial Electromechanical Delay in patients with COPD and hyperinflation
M. Valentino (Napoli (NA), Italy), A. Saglia (Napoli (NA), Italy), M. D'Amato (Napoli (NA), Italy), M. Maniscalco (Benevento, Italy), P. Ambrosino (Benevento, Italy), M. Conte (Napoli (NA), Italy), V. Russo (Napoli (NA), Italy), A. Molino (Napoli (NA), Italy)
| |
Revefenacin (REV) improves health status and dyspnea regardless of baseline symptom status in chronic obstructive pulmonary disease (COPD): a post hoc analysis of phase 3 trials
G. Ferguson (Farmington Hills, United States of America), T. Siler (St. Charles, United States of America), D. Lombardi (South San Francisco, United States of America), G. Crater (South San Francisco, United States of America)
| |
Evaluation of the clinical efficacy of the fluticasone-salmeterol fixed dose combination (FDC) in Greek patients with Chronic Obstructive Pulmonary Disease-AEOLOS study
I. Markou (Pikermi, Greece), S. Tryfon (Thessaloniki, Greece), P. Steiropoulos (Alexandroupolis, Greece), A. Ginis (Pikermi, Greece), A. Athanassiou (Pikermi, Greece), N. Grekas (Pikermi, Greece)
| |
Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study.
K. Beeh (Wiesbaden, Germany), P. Kuna (Lodz, Poland), I. Viaud (Parma, Italy), A. Guasconi (Parma, Italy), M. Corradi (Parma, Italy), G. Georges (Parma, Italy)
| |
Role of inhaled corticosteroids on recurrent bronchial infection by potentially pathogenic bacteria in patients with COPD
L. Ramon Clar (Palma, Spain), F. Verdu Rivera (Palma, Spain), N. Toledo Pons (Palma, Spain), A. Iglesias Coma (Palma, Spain), C. Juan Nicolau (Palma, Spain), C. López Causape (Palma, Spain), P. Fralie Ribot (Palma, Spain), A. Oliver (Palma, Spain), F. García Cosío (Palma, Spain)
| |
The distribution of blood eosinophil count in the IMPACT South America population
J. Jardim (Sao Paulo, Brazil), V. Di Boscio (London, United Kingdom), G. Levy (Panamao, Panama), A. Raimondi (Buenos Aires, Argentina), A. Lijavetzky (Buenos Aires, Argentina), L. Jotimliansky (Buenos Aires, Argentina), S. Kilbride (Midddlesex, United Kingdom), C. Soares (Rio de Janeiro, Brazil), D. Lipson (London, United Kingdom)
| |
Stability of eosinophils in blood in patients with chronic obstructive pulmonary diseasee (COPD) and one hospital admission
E. Garay Llorente (Barakaldo, Spain), E. Tabernero Huguet (Barakaldo, Spain), B. Gonzalez Quero (Barakaldo, Spain), L. Ansola Marlasca (Barakaldo, Spain), J. Andia Iturrate (Barakaldo, Spain), B. Ortiz De Urbina Antia (Barakaldo, Spain), M. Iriberri Pascual (Barakaldo, Spain), P. Sobradillo Ecenarro (Barakaldo, Spain)
| |
Stability of sputum and blood eosinophil levels in COPD
A. Beech (Manchester, United Kingdom), S. Lea (Manchester, United Kingdom), U. Kolsum (Manchester, United Kingdom), N. Jackson (Manchester, United Kingdom), P. Hitchen (Manchester, United Kingdom), S. Wolosianka (Manchester, United Kingdom), D. Singh (Manchester, United Kingdom)
| |
The impact of eosinophil levels on current prescribing in COPD
L. Flint (Leeds, United Kingdom), D. Dimov (Leeds, United Kingdom)
| |
Burden of disease among exacerbating patients with eosinophil COPD treated with triple therapy in Spain
E. Mariscal (Madrid, Spain), M. Miravitlles (Barcelona, Spain), G. Sánchez (Madrid, Spain), A. García (Madrid, Spain), M. Cuesta (Barcelona, Spain), E. Uría (Barcelona, Spain), B. Alcázar (Granada, Spain), F. García-Río (Madrid, Spain)
| |
Microbiome Use to Stratify Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (MUSIC) trial: baseline data and impact of inhaled corticosteroid withdrawal in severe COPD with frequent exacerbations
H. Richardson (Dundee (Angus), United Kingdom), C. Clarke (Dundee (Angus), United Kingdom), M. Lonergan (Dundee (Angus), United Kingdom), H. Barclay (Dundee (Angus), United Kingdom), M. Crichton (Dundee (Angus), United Kingdom), J. Pollock (Glasgow, United Kingdom), S. Finch (Dundee (Angus), United Kingdom), P. Billingham (Dundee (Angus), United Kingdom), F. Hussain (Dundee (Angus), United Kingdom), A. Mackenzie (Dundee (Angus), United Kingdom), D. Cassidy (Dundee (Angus), United Kingdom), M. Band (Dundee (Angus), United Kingdom), A. Smith (Glasgow, United Kingdom), M. Paracha (Blackpool, United Kingdom), G. Chowdhury (Edinburgh, United Kingdom), D. Dhasmana (Kirkcaldy, United Kingdom), R. Chaudhuri (Glasgow, United Kingdom), P. Short (Dundee (Angus), United Kingdom), H. Keir (Dundee (Angus), United Kingdom), A. Dicker (Dundee (Angus), United Kingdom), J. Chalmers (Dundee (Angus), United Kingdom)
| |